Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Eli Lilly

Novartis

Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.

3 Large Drug Stocks That Have Outperformed Industry YTD

Diabetes-turned-weight loss drug Mounjaro is more effective for shedding off extra pounds than its ultra-popular counterpart, Ozempic, according to a new study.

Ozempic is not the most effective weight-loss drug on the market: study

Cboe Global Markets

InterContinental Hotels Group

Gartner

Progressive

We have narrowed our search to five large-cap stocks with more upside for 2024. These are: IT, PGR, CBOE, IHG, NVO.

5 Must-Buy Stocks at 52-Week High With More Upside for 2024

The success of Novo Nordisk's diabetes drug Ozempic and weight loss drug Wegovy has driven the company's growth leading to market outperformance. Novo Nordisk's success could continue as both Ozempic and Wegovy are being studied for other conditions. The market for obesity is also growing rapidly. Cardiovascular disease could be the next focus for the company as it expands further from its core diabetes treatments.

Novo Nordisk: Plenty More Room To Run Despite Its Hefty Valuation

Novo Nordisk's stock continues to surge as greedy investors exploit surging momentum, as they fear missing out on further potential gains. The company's impressive Q3 earnings results suggest the upward momentum could continue. I also have not assessed sell signals that could stall its momentum yet. Novo Nordisk's plans to broaden its geographical coverage and expand its production capacity should support investors' confidence in sustainable demand/supply dynamics.

Novo Nordisk: Massive Reality Check Awaits Greedy Investors

Novo Nordisk has surpassed Nestle as the largest developed-market stock outside of the US, indicating the success of the GLP-1 drug segment. The company had a strong Q3 with a 29% YoY increase in revenue and raised its full-year outlook. Analysts expect significant earnings growth for Novo Nordisk in 2023 and beyond, and the stock is priced for strong growth ahead.

Novo Nordisk: Healthy Gains Ahead, EPS Growth Seen, Technical Strength

PGT Innovations

Novo Nordisk and PGT Innovations continue to show relative strength and are among the best stocks to buy now.

New Highs: Novo Nordisk, PGT Innovations Among Best Stocks To Buy Now

Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic diseases.

Novo Nordisk (NVO) to Expand Manufacturing Site in France

Pharmaceutical name Novo Nordisk A/S (NYSE:NVO) is up 1.6% at $104.93 at last glance, earlier hitting a fresh record peak of $105.30.

Pharma Stock Hits Record High After Expansion Plans

Assurant

Centrus Energy

Modine Manufacturing

Paymentus Holdings

NVO, PAY, AIZ, MOD and LEU have been added to the Zacks Rank #1 (Strong Buy) List on November 24, 2023.

New Strong Buy Stocks for November 24th

Apple

DraftKings

Microsoft

NVIDIA

Riot Blockchain

Taiwan Semiconductor Manufacturing

The story of the stock market in 2023 has largely been about optimism around AI tinged by the continued threat of recession. Generative AI has propelled tech shares much higher.

7 Stocks Set to Capitalize on the Coming Year-End Rally

Weight loss drug developer Novo Nordisk (NYSE:NVO) has announced US$2.3 billion will be spent on ramping up production in France. Set to boost capacity, quality control lab space, aseptic and finished production processes at the drug giant's Chartres site, southwest of Paris, Novo Nordisk said the move would preempt future demand.

Novo Nordisk to invest $2 billion in France production boost

Novo Nordisk makes Ozempic and Wegovy, two hit drugs that treat obesity. Supply is a major issue right now, with the firm warning a European regulator it may ration Ozempic.

Ozempic maker plans manufacturing blitz as market for the drug is expected to top $100 billion in 2030

Bagsværd, Denmark, 23 November 2023 – Novo Nordisk today announced the investment of more than 16 billion Danish kroner (2.1 billion euros) starting in 20231 to expand the existing production site in Chartres, France, for the current and future product portfolio within serious chronic diseases.

Novo Nordisk invests more than 16 billion Danish kroner in expansion of production facilities in Chartres, France

Boeing

Palantir Technologies

The hype seems eerily familiar, but Novo Nordisk's weight-loss drug may well meet lofty sales expectations. Despite plenty of headaches, Boeing is showing strength in front of a massive wave of demand for new passenger jets.

$3,000 Invested in These 3 Top Stocks Could Make You Rich in 10 Years

Novo Nordisk said on Thursday it will launch its hugely popular Wegovy obesity drug in Japan on Feb. 22 next year.

Novo Nordisk to launch obesity drug Wegovy in Japan in February

Danish drug maker Novo Nordisk said on Thursday it would invest more than 16 billion crowns ($2.34 billion) in the expansion of production facilities in Chartres in France.

Novo Nordisk invests $2.3 mln in France to boost output

French President Emmanuel Macron will on Thursday inaugurate a 2.1 billion euro ($2.3 billion) investment by Danish pharmaceutical company Novo Nordisk in France, his office said, pitching it as a sign of newly restored French industrial competitiveness.

Macron to unveil 2.1 bln eur Novo Nordisk pharma investment in France

Costco

NIKE

What will the next decade bring and how will we be living in the 2030s? It's a question marketing professionals and traders spend a lot of time trying to figure out as they forecast which stocks will define and dominate the next decade for consumers.

3 Consumer Goods Stocks That Will Define the Next Decade

Shortages of Novo Nordisk's diabetes drugs Ozempic and Victoza will deteriorate in the fourth quarter of 2023 and persist throughout 2024, the Danish company and the EU's drug regulator said, as surging demand from people seeking to lose weight shows no sign of letting up.

Novo Nordisk says diabetes drugs shortages will persist through 2024

Pfizer

Medicare's decades-old exclusion of weight-loss drug coverage is coming under scrutiny amid mounting evidence that Wegovy and similar medications have health benefits that extend well beyond shedding pounds.

Medicare's exclusion of weight-loss drug coverage under fire

Weight loss was the talk of this earnings season, making names such as Wegovy, Ozempic and Mounjaro the water-cooler discussion that companies across the globe could not ignore.

Wegovy craze was all the rage on Q3 earnings calls

Popular weight loss drugs Wegovy and Zepbound will soon be available in pill form. Pharmaceutical giants Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) are actively promoting pill versions of their successful weight-loss drugs, expected to hit the market as early as next year, Bloomberg reported.

Weight loss drugs Wegovy and Zepbound to debut in pill form

AstraZeneca

Chubb

Eaton

NXP Semiconductors

Shell PLC

Investors in Eurozone stocks have been taken for a roller-coaster ride thus far this year. These stocks performed strongly during the first several months of 2023 as the pace of economic activity and company profits beat market expectations.

When Will It Again Be Safe To Invest In Eurozone Stocks?

Lululemon Athletica

What do stretchy pants, fat-loss drugs, and sports betting have in common? Each of these is powering some of the strongest mega-trends on Wall Street.

3 Industry Titans Benefitting from Mega Trends

News for Novo Nordisk Stock (NVO)